1-(3,4-二苄基氧基苯基)-2-硝基丙烯 | 62932-96-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(3,4-二苄基氧基苯基)-2-硝基丙烯
• 英文名称: 1-(3,4-dibenzyloxyphenyl)-2-nitropropene
• 英文别名: 1ξ-(3,4-Dibenzyloxy)-2-nitro-propen；1-(3,4-Dibenzyloxyphenyl)-2-nitropropen；4-(2-nitroprop-1-enyl)-1,2-bis(phenylmethoxy)benzene
• CAS: 62932-96-1
• 化学式: C₂₃H₂₁NO₄
• mdl: MFCD02258810
• 分子量: 375.424
• InChiKey: PEDOADQHWFZFKP-UHFFFAOYSA-N

物化性质

• 熔点：
  117 °C
• 沸点：
  546.2±45.0 °C(Predicted)
• 密度：
  1.201±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、乙酸乙酯

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  64.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(3,4-二苄基氧基苯基)-2-硝基丙烯 在 盐酸 、 iron(III) chloride 、 铁粉 作用下， 生成 (S)-1-(3,4-dibenzyloxyphenyl)-2-aminopropane
  参考文献：
  名称：

  [EN] SAFER PSYCHOACTIVE COMPOSITIONS
  [FR] COMPOSITIONS PSYCHOACTIVES PLUS FIABLES

  摘要：

  Provided are therapeutic combinations comprising hallucinogenic agents and entactogenic agents. Also provided are compositions, such as pharmaceutical compositions, comprising such combinations and methods of using the same. In some embodiments, the entactogenic agent is a non-racemic entactogen. In some embodiments, a provided therapeutic combination or composition thereof is administered to a subject to treat a mental health condition, a substance abuse disorder, or a condition that features impaired social reward or social cognition, such as social anxiety and autism. In some aspects, the features of the combinations, e.g., neuromodulatory activity, improve physiological and psychological effects by, for example, reducing potential for abuse, neurotoxic effects, and improving subjective experience and therapeutic efficacy.

  公开号：

  WO2023283386A2
• 作为产物：
  描述：

  3,4-二苄氧基苯甲醛 、 硝基乙烷 在 ammonium acetate 作用下， 反应 17.0h， 以96%的产率得到1-(3,4-二苄基氧基苯基)-2-硝基丙烯
  参考文献：
  名称：

  Synthesis and capillary electrophoretic analysis of enantiomerically enriched reference standards of MDMA and its main metabolites

  摘要：

  Enantiomerically-enriched (S)-3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites (S)-4-hydroxy-3-methoxymethamphetamine (HMMA) and (S)-3,4-dihydroxymethamphetamine (HHMA) were prepared for unequivocal identification of the differential enantioselective metabolism of these compounds as well as for its application in the analysis of biological samples. Capillary electrophoresis with cyclodextrin derivatives and a chemical correlation of (S)-MDMA. (S)-HMMA and (S)-HHMA has been performed to assign the absolute stereochemistry of major isomers in analytical standards enriched with such enantiomers. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00367-4

文献信息

• PRATESI; LAMANNA; GRANA, Farmaco, Edizione Scientifica, 1964, vol. 19, p. 529 - 536
  作者：PRATESI、LAMANNA、GRANA

  DOI：——

  日期：——
• Exploring Nitrostyrene as a Scaffold for a New Class a of Monoamine Oxidase Inhibitors
  作者：Joana Reis、Catarina Oliveira、Nuno Milhazes、Dolores Vina、Fernanda Borges

  DOI：10.2174/157018012804586888

  日期：2012.12.1

  With the ultimate purpose of finding out the structural features that are relevant for MAO inhibitory activity and selectivity towards MAO-B isoform, a series of compounds encompassing a beta-nitrostyrene moiety was designed and the in vitro inhibitory activity was evaluated. In the present work, we report the synthesis and the pharmacological evaluation of a series of functionalized derivatives of beta-methyl-beta-nitrostyrene with distinct substitution patterns in the phenyl ring, namely hydroxyl, methoxy, benzyloxy and methylenedioxy. All the studied compounds were substituted in meta and para positions of the phenyl ring related to the nitrovinyl side chain. The synthesized compounds were evaluated towards both human MAO isoforms, displaying some of them activities in the low micromolar range. Particularly compound 6 (a methylenedioxy derivative) exhibits high potency and selectivity towards MAO-B.
• [EN] ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND METHODS OF THEIR USE<br/>[FR] COMPOSITIONS ENTACTOGÈNES ÉNANTIOMÈRES ET LEURS MÉTHODES D'UTILISATION
  申请人：ARCADIA MEDICINE INC

  公开号：WO2022256720A3

  公开（公告）日：2023-01-19
• [EN] SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES<br/>[FR] VOIES DE SYNTHÈSE POUR ACCÉDER À DES PROMÉDICAMENTS DE MDMA À L'AIDE D'INTERMÉDIAIRES CONTRÔLÉS ET NON CONTRÔLÉS
  申请人：[en]MIND MEDICINE, INC.

  公开号：WO2023028022A1

  公开（公告）日：2023-03-02

  A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt.